Skip to results

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 1 to 50 of 310

Guidance and quality standards awaiting development
TitleType
10395 - Aprocitentan for treating resistant hypertension TS ID 10395Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095Technology appraisal guidance
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823Technology appraisal guidance
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]Technology appraisal guidance
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture TS ID 11870Technology appraisal guidance
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]Technology appraisal guidance
AI-supported colorectal polyp detectionHealth technology evaluation
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830Technology appraisal guidance
Ambulatory pulmonary artery pressure monitoring devicesDiagnostics guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967Technology appraisal guidance
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasiaMedical technologies guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer ID 6200Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Technology appraisal guidance
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]Technology appraisal guidance
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer TSID 10710Technology appraisal guidance
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]Technology appraisal guidance
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867Technology appraisal guidance
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis TS ID 12016Technology appraisal guidance
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine TS ID 11939Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma TS ID 11987Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]Technology appraisal guidance
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888Technology appraisal guidance
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Technology appraisal guidance
Caval valve implantation for tricuspid regurgitationInterventional procedures guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All